Trial | NCT01473251  Report issue

Official Title

Analysis of Growth Factors in Patients Undergoing Lucentis or Avastin Injections for Diabetic Macular Edema and Exudative Macular Degeneration

  • Phase

    N/A

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Study Participants

    16
The purpose of this study is to measure biomarkers in the vitreous of patients undergoing Lucentis or avastin treatment.
Study Started
Nov 30
2011
Primary Completion
Apr 30
2014
Study Completion
Apr 30
2014
Last Update
Dec 17
2014
Estimate

Drug Avastin

1.25 mg monthly for 4 months

Drug Avastin

1.25 mg monthly for 4 months

Drug Lucentis

0.5 mg monthly for 4 months

Avastin for Diabetic Macular Edema Active Comparator

1.25 mg avastin monthly for 4 months

Avastin for Exudative Macular Degeneration Active Comparator

1.25 mg Avastin monthly for 4 months

Lucentis for Exudative Macular Degeneration Active Comparator

0.5 mg Lucentis monthly for 4 months

Criteria 

Inclusion Criteria:

Male or female age 18 to 85 with diabetes and hemoglobin A1C </= 10, or exudative macular degeneration.
Diabetic macular edema with average retinal thickness central subfield >/= 290um.

Exclusion Criteria:

Macular atrophy/fibrosis.
Ocular anti-VEGF treatment within 3 months.
Treatment with topical or oral carbonic-anhydrase inhibitor within one month
Laser photocoagulation within 3 months (diabetic cohort)
No Results Posted